11:27 AM EST, 01/08/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Wednesday that the US Department of Defense has exercised a contract option to buy around $20 million of the company's BioThrax anthrax vaccine.

In December, the company shipped about $7 million of the pre-exposure vaccine to the Pentagon for distribution among all six branches of the US military, with the remaining deliveries expected over the rest of 2025, it said.

The purchase was authorized through the company's existing procurement contract with the Defense Department and its Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

Emergent last month also disclosed a $50 million contract option to supply up to $50 million of its Cyfendus anthrax vaccine to the federal government expected to be completed by April.

Price: 9.99, Change: -0.29, Percent Change: -2.80